EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis

Daniel E Weiner, Thilo Schaufler iD, Kieran McCafferty, Kamyar Kalantar-Zadeh iD, Michael Germain iD, Despina Ruessmann, Isabelle Morin, Frédérique Menzaghi, Warren Wen, Sonja Ständer

Nephrology Dialysis Transplantation · 28.06.2024 · 39 (7) · 1125-1137

DOI: 10.1093/ndt/gfad245 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 15.11.2023. Verfasst von Daniel E Weiner und 9 weiteren Autor:innen. Beteiligte Einrichtung: William B. Schwartz MD Division of Nephrology, Tufts Medical Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Pruritus, Renal Dialysis, Quality of Life. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Vifor Fresenius Medical Care Renal Pharma Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Poor sleep quality is associated with higher mortality and lower quality of life in patients with chronic kidney disease–associated pruritus (CKD-aP). Difelikefalin reduces itch in patients with CKD-aP undergoing haemodialysis (HD). This post hoc analysis of the Phase 3 difelikefalin studies (Study 3105 and the pooled dataset from KALM-1 and KALM-2) evaluated whether itch reduction in individuals with CKD-aP improved sleep quality.

Methods

Itch intensity was assessed in patients undergoing HD who had moderate-to-severe CKD-aP treated with intravenous difelikefalin (0.5 µg/kg, three times weekly) (N = 222, Study 3105; N = 426, KALM-1 and -2) or placebo (N = 425, KALM-1 and -2) for 12 weeks, using the Worst Itch Intensity Numerical Rating Scale (WI-NRS). Sleep quality was assessed using the sleep disability question of the 5-D Itch Scale (5-D SDQ) in all studies and, in Study 3105, with the Sleep Quality Numeric Rating Scale (SQ-NRS).

Results

Greater improvements in sleep quality were observed in patients with ≥3-point versus <3-point WI-NRS improvement using SQ-NRS in Study 3105 [mean (95% confidence interval) −5.2 (–5.6, −4.8) vs −1.5 (–2.0, −1.0)] and 5-D SDQ in KALM-1 and -2 [–1.8 (–2.1, −1.6) vs −0.8 (–1.1, −0.4)]. SQ-NRS and WI-NRS scores were highly correlated at both baseline and Week 12 in Study 3105 (Spearman correlation coefficient: 0.77 and 0.84, respectively). Correlations were also observed between 5-D SDQ and WI-NRS scores in Study 3105 and KALM-1 and -2.

Conclusions

In patients undergoing HD with moderate-to-severe CKD-aP, itch reduction with intravenous difelikefalin was associated with improved sleep quality. As disturbed sleep may contribute to mortality and morbidity in CKD-aP, difelikefalin may help to address a major clinical burden by improving sleep quality, secondary to itch relief. Trial Registration KALM-1 (NCT03422653), KALM-2 (NCT03636269), Study 3105 (NCT03998163).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PruritusRenal DialysisQuality of LifeHumansMaleFemaleMiddle AgedAgedDouble-Blind MethodSleep Wake DisordersRenal Insufficiency, ChronicFollow-Up StudiesPrognosisSleep QualityPiperidines

Stichwörter der Autor:innen

chronic kidney disease–associated pruritusdifelikefalinhaemodialysisitchsleep

Substanzen

difelikefalinPiperidines

Autor:innen und Institutionen

  • William B. Schwartz MD Division of Nephrology, Tufts Medical Center, Boston, MA, USA.
  • CSL Vifor, Glattbrugg, Switzerland.
  • The Royal London Hospital-Barts Health NHS Trust, London, UK.
  • Division of Nephrology and Hypertension and Kidney Transplantation, University of California, Irvine, Irvine, CA, USA.
  • Baystate Medical Center, Springfield, MA, USA.
  • CSL Vifor, Meyrin, Switzerland.

ORCID-Profile: Thilo Schaufler, Kamyar Kalantar-Zadeh, Michael Germain

Förderung

  • Wellcome Trust
  • Vifor Fresenius Medical Care Renal Pharma Ltd

Zitieren

APA

Weiner, D. E., Schaufler, T., McCafferty, K., Kalantar-Zadeh, K., Germain, M., Ruessmann, D., Morin, I., Menzaghi, F., Wen, W., & Ständer, S. (2024). Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis. Nephrology Dialysis Transplantation, 39(7), 1125-1137. https://doi.org/10.1093/ndt/gfad245

Vancouver

Weiner DE, Schaufler T, McCafferty K, Kalantar-Zadeh K, Germain M, Ruessmann D, et al. Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis. Nephrology Dialysis Transplantation. 2024;39(7):1125-1137. doi:10.1093/ndt/gfad245

BibTeX
@article{Weiner2024,
  author = {Weiner, Daniel E and Schaufler, Thilo and McCafferty, Kieran and Kalantar-Zadeh, Kamyar and Germain, Michael and Ruessmann, Despina and Morin, Isabelle and Menzaghi, Frédérique and Wen, Warren and Ständer, Sonja},
  title = {Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  volume = {39},
  number = {7},
  pages = {1125--1137},
  doi = {10.1093/ndt/gfad245}
}
Kostenlos starten →